[177Lu]Lu-CHX-A''-DTPA-7F5

[177Lu]Lu-CHX-A''-DTPA-7F5 is a preclinical PSCA-targeted radiopharmaceutical radioimmunoconjugate being investigated for prostate cancer imaging and potential radioimmunotherapy. The agent consists of the anti-prostate stem cell antigen monoclonal antibody 7F5 conjugated to the bifunctional chelator CHX-A''-DTPA and labeled with lutetium-177, enabling selective binding to PSCA-expressing tumor cells and delivery of tumor-localized beta radiation for theranostic use. In reported preclinical studies, the compound showed high radiochemical purity and stability, preserved antigen binding after labeling, high uptake in PSCA-positive xenografts, and favorable SPECT or CT tumor-to-background contrast, supporting its development as an alternative approach for prostate cancers that do not adequately express PSMA.

Other names

lutetium-177 CHX-A''-DTPA-7F5177Lu-labeled 7F5anti-PSCA 7F5 radioimmunoconjugateanti-PSCA7F5 radioimmunoconjugateanti-PSCA-7F5 radioimmunoconjugate